Loading...
Please wait, while we are loading the content...
Similar Documents
Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis.
| Content Provider | Europe PMC |
|---|---|
| Author | Gemelli, Maria Cortinovis, Diego Luigi Baggi, Alice di Mauro, Pierluigi Calza, Stefano Berruti, Alfredo Grisanti, Salvatore Rota, Matteo |
| Editor | Nadal, Ernest |
| Copyright Year | 2022 |
| Abstract | Simple SummaryMany clinical trials have investigated the role of Immune Checkpoint Inhibitors (ICIs) in pleural mesothelioma (PM), with contrasting results. We performed a systematic review and meta-analysis of clinical trials testing single-agent ICIs or combined treatments in PM patients. Combined ICI treatments have higher Progression Free Survival (PFS) and Overall Survival (OS) rates when compared with single agents but a similar Overall Response Rate (ORR) and a higher rate of adverse events (AEs). ICI efficacy was independent of the treatment line.AbstractMany clinical trials have investigated the role of ICIs in PM, with contrasting results. We performed a systematic review and meta-analysis of clinical trials testing single-agent anti-Programmed Death -1 (PD-1)/Programmed Death-Ligand 1 (PD-L1), anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) or combined treatment in PM patients, analyzing response and survival rate as well as safety data. We selected 17 studies including 2328 patients. Both OS and PFS rates were significantly higher with combined ICI treatments than with single agent anti-PD-1/PD-L1 (p < 0.001 and p = 0.006, respectively) or anti CTLA-4 (p < 0.001) treatments. ORR and DCR for all ICI treatments were 20% (95% CI 13–27%) and 56% (95% CI 45–67%), respectively, and they did not significantly differ between combined and single agent treatments (p = 0.088 and p = 0.058, respectively). The 12-month OS and 6-month PFS rates did not differ significantly (p = 0.0545 and p = 0.1464, respectively) among pre-treated or untreated patients. Combined ICI treatments had a significantly higher rate of Adverse Events (AEs) (p = 0.01). PD-L1-positive patients had a higher probability of response and survival. In conclusion, combined ICI treatments have higher efficacy than single agents but are limited by higher toxicity. Efficacy was independent of treatment line, so a customized sequential strategy should still be speculated. PD-L1 expression could influence response to ICIs; however, reliable biomarkers are warranted. |
| Journal | Cancers |
| Volume Number | 14 |
| PubMed Central reference number | PMC9775536 |
| Issue Number | 24 |
| PubMed reference number | 36551550 |
| e-ISSN | 20726694 |
| DOI | 10.3390/cancers14246063 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2022-12-09 |
| Access Restriction | Open |
| Rights License | Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). © 2022 by the authors. |
| Subject Keyword | pleural mesothelioma immune checkpoint inhibitors immunotherapy anti PD-1/PD-L1 anti CTLA-4 |
| Content Type | Text |
| Resource Type | Article |
| Subject | Oncology Cancer Research |
